RUNX1 and leukemia: In recent years, PRMT1 has been implicated in AML1-ETO leukemia (Shia et al., 2012) and some solid tumors (Mathioudaki et al., 2011, Yoshimatsu et al., 2011); however, in vivo transformation data are still required to firmly establish a functional link in the actual disease pathogenesis.